POSTER PRESENTATIONS: Saturday 25 June: NAFLD: Therapy
SAT106 - TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study

https://doi.org/10.1016/S0168-8278(22)01748-2Get rights and content

Cited by (0)

View Abstract
Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.